Compare PDSB & CYCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDSB | CYCU |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 9.5M |
| IPO Year | 2015 | 2021 |
| Metric | PDSB | CYCU |
|---|---|---|
| Price | $0.21 | $3.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.00 | $7.00 |
| AVG Volume (30 Days) | 2.7M | ★ 7.5M |
| Earning Date | 05-14-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,771,485.00 |
| Revenue This Year | N/A | $8.92 |
| Revenue Next Year | N/A | $10.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.16 |
| 52 Week High | $1.55 | $7.13 |
| Indicator | PDSB | CYCU |
|---|---|---|
| Relative Strength Index (RSI) | 21.28 | 86.39 |
| Support Level | $0.20 | $0.69 |
| Resistance Level | $0.77 | $4.46 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.00 | 0.19 |
| Stochastic Oscillator | 3.09 | 91.05 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Cycurion Inc. provides information technology security solutions through its subsidiaries. The company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company has one reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).